Radius Health (NASDAQ: RDUS) reported Q4 EPS of ($0.29), $0.48 better than the analyst estimate of ($0.77). Revenue for the quarter came in at $55.67 million versus the consensus estimate of $53.29 million.

“I am very pleased that TYMLOS exited 2019 with a December majority share of postmenopausal osteoporosis patients starting on anabolic therapy in the U.S. market. In 2020, we have three critical objectives: continue expanding our market share for TYMLOS, reach anabolic total market share leadership, and complete recruitment in our three pivotal Phase 3 studies,” said Jesper Hoeiland, President and Chief Executive Officer of Radius.

GUIDANCE:

Radius Health sees FY2020 revenue of $220-235 million, versus the consensus of $246.17 million.

For earnings history and earnings-related data on Radius Health (RDUS) click here.